102 0 Kommentare GeneThera enters into a collaboration agreement with an International Construction Advisor Company to build a network of zoonotic diseases laboratory facilities - Seite 2

"We are very excited to partner with the team over at GeneThera, Inc. to help build laboratories that will provide safe and efficient diagnostic environments while resetting facility standards for future infectious disease research," said Jack Christensen, director at Cumming. "Being able to leverage all of the specialized knowledge of Cumming's nationwide life-sciences team allows us to implement much-needed lessons learned in lab design, space, and construction requirements from the current pandemic to deliver the next generation of laboratory environments."

About GeneThera, Inc.

GeneThera is a biotechnology company developing molecular robotic/AI diagnostics and therapeutics in an effort to control and eradicate zoonotic diseases. GeneThera developed molecular assays for BSE and Mycobacterium Avium Paratuberculosis (MAP). MAP is an infectious organism causing Paratuberculosis in dairy cows that is also linked to Crohn’s Disease in humans. We utilize these technologies to minimize the spread of animal infectious organisms such as SARS-CoV-2 to humans. Management and prevention of zoonotic diseases is crucial to human and animal health on a global scale.

About Cumming

Cumming is an international project and cost management firm with 30 domestic and five international offices, and approximately 1,000 team members. Since opening for business in 1996, Cumming has provided efficient and cost-effective solutions to ensure that projects in the commercial, hospitality, retail, entertainment, education, healthcare, and high-end residential sectors are executed on time and within budget. Cumming provides a solutions-oriented suite of services that specifically addresses its clients' unique challenges, thus enabling them to achieve extraordinary results. For more information, please visit www.ccorpusa.com.

This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "intends," "believes," and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

For further information, please contact: